The FamilyStrong Pilot Randomized Trial
6 de agosto de 2026 atualizado por: James N Odom, University of Alabama at Birmingham
Brief Distress Support for Family Caregivers of Persons With Advanced Cancer: The FamilyStrong Pilot Randomized Trial
When someone is diagnosed with advanced cancer, their family members and close friends often take on the role of caregiver, providing emotional support and complex medical care for their loved one, often for up to eight hours a day.
This responsibility can take a significant toll, leaving family caregivers overwhelmed, highly stressed, and without access to the support they need.
Research shows that when caregivers are struggling, both they and the patients they care for suffer.
Caregiver distress has been linked to poor quality of life for patients and greater emotional strain on families.
Despite the well-documented emotional and physical burdens on family caregivers, most cancer centers do not include structured support services to help them cope and navigate challenges.
Many caregivers do not even realize help is available, leading to feelings of isolation and burnout.
Yet, despite the critical role caregivers play in cancer care, there are very few programs designed to support them in ways that are both effective and widely accessible.
To address this urgent need, our team has developed FamilyStrong, a novel intervention specifically designed to fill this gap and support family caregivers in real-world cancer care settings.
FamilyStrong is a brief and easy-to-use program that helps family caregivers recognize and manage distress while connecting them to the right support.
Unlike many caregiver support programs that require extensive time and highly trained specialists, FamilyStrong is led by lay navigators, who are trained individuals who can guide caregivers through challenges and connect them with appropriate resources.
The program uses a simple distress screening tool to quickly assess how caregivers are coping and then tailors support to their specific needs.
We will test FamilyStrong in a small pilot study with 60 caregivers of patients newly diagnosed with advanced cancer.
Over a period of 24 weeks, we will evaluate how well the program works, whether caregivers find it helpful, and whether it improves caregiver and patient well-being compared to usual care.
Specifically, we will measure whether caregivers experience lower stress, improved quality of life, and fewer unmet needs when they participate in the FamilyStrong program.
After this study, we will use these results and our experiences to inform a larger clinical trial to confirm FamilyStrong's benefits and eventually expand the program nationwide.
By providing caregivers with practical, effective support, FamilyStrong has the potential to improve the quality of life for both caregivers and cancer patients, ensuring that families facing cancer receive the help they need when they need it most.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Descrição detalhada
This is a single-site, two-arm, parallel-group, NIH Stage IB pilot randomized clinical trial evaluating FamilyStrong, a brief caregiver distress-screening and support intervention. Sixty adult family caregivers of people with advanced cancer will be randomized 1:1 to FamilyStrong or usual care. The caregiver is the unit of randomization and the direct recipient of the intervention. Up to 60 patients may also participate in research data collection, but patient participation is optional and patients do not receive the FamilyStrong intervention.
Caregivers assigned to FamilyStrong will receive approximately monthly telephone contacts for 24 weeks from a trained lay navigator. During each contact, the navigator will administer the FamilyStrong Caregiver Distress Thermometer and caregiver-specific Problem List, identify the caregiver's highest-priority concerns and desired assistance, and provide individualized support. Support may include emotional support, information and education, collaborative problem-solving, action planning, resource navigation, consultation, or referral to appropriate clinical or community services. Caregivers may accept, decline, or postpone any offered assistance.
FamilyStrong caregivers will also receive the FamilyStrong Navigation Companion, a caregiver-directed resource containing monthly check-in pages, caregiving resources, medical and appointment organizers, problem-solving and action-planning tools, and space for notes. Caregivers assigned to usual care will continue to use services ordinarily available through the cancer center and community. Participants in both groups will receive information about available cancer-center and family-support resources.
Study assessments will occur at baseline and approximately 24 weeks. Intervention-group caregivers will also be invited to complete a post-intervention qualitative interview about their experience with FamilyStrong and the study procedures. As a pilot trial, the study is designed primarily to evaluate acceptability, feasibility, intervention delivery, and the practicality of trial procedures, while estimating preliminary between-group effects to inform a future, larger efficacy trial. It is not powered to provide a definitive test of intervention effectiveness.
Tipo de estudo
Intervencional
Inscrição (Estimado)
120
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Sally Engler, MPH
- Número de telefone: 205-996-7564
- E-mail: sengler@uab.edu
Estude backup de contato
- Nome: J. Nicholas Odom, PhD, RN
- Número de telefone: 205-934-7597
- E-mail: dionneod@uab.edu
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- University of Alabama at Birmingham
-
Contato:
- Sally Engler, MPH
- Número de telefone: 205-996-7564
- E-mail: sengler@uab.edu
-
Contato:
- James N Odom, PhD, RN
- Número de telefone: 2059347597
- E-mail: dionneod@uab.edu
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
CAREGIVERS:
1) ≥18 years of age; 2) self-endorsing or identified by the patient as "a relative, friend, or partner that has a close relationship with you and who assists with your health and medical care and who may or may not live in the same residence as you and who is not paid for their help"; 3) caring for a patient with advanced-stage cancer (see definition under Patient Inclusion criteria below) who is not enrolled in hospice; 4) caregivers will NOT need to have a patient willing to participate; and 5) able to speak and read English and complete baseline measures.
PATIENTS:
- ≥18 years of age; 2) screened within 60 days of an oncology visit where the patient had documentation of a new diagnosis of an advanced stage cancer, defined as metastatic and/or recurrent/progressive stage III/IV cancer, including brain, lung, breast, gynecologic, head and neck, gastrointestinal, genitourinary cancer, melanoma; and hematologic malignancies; and 3) able to speak and read English and complete baseline measures.
Exclusion Criteria:
CAREGIVERS:
1) Self-reported active, untreated mental illness (i.e., schizophrenia, bipolar disorder, or major depressive disorder), dementia, active suicidal ideation, uncorrected hearing loss, or active substance abuse.
PATIENTS:
- Receiving hospice per EHR; 2) Per EHR, active, untreated mental illness (i.e., schizophrenia, bipolar disorder, or major depressive disorder), dementia, suicidal ideation, uncorrected hearing loss, or substance abuse.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: FamilyStrong
Caregivers randomized to FamilyStrong will receive approximately monthly telephone-based distress screening and individualized support from a trained lay navigator for 24 weeks.
During each encounter, the navigator will administer the FamilyStrong Caregiver Distress Thermometer and Problem List, identify the caregiver's priority concerns and desired assistance, and provide support as appropriate, including emotional support, information and education, collaborative problem-solving, action planning, resource navigation, consultation, or referral.
Participants will also receive the FamilyStrong Navigation Companion, a caregiver-directed resource containing check-in pages, caregiving resources, medical and appointment organizers, worksheets, and notes pages.
Additional follow-up contacts may occur based on caregiver needs.
|
Caregivers randomized to FamilyStrong will receive approximately monthly telephone-based distress screening and individualized support from a trained lay navigator for 24 weeks.
During each encounter, the navigator will administer the FamilyStrong Caregiver Distress Thermometer and Problem List, identify the caregiver's priority concerns and desired assistance, and provide support as appropriate, including emotional support, information and education, collaborative problem-solving, action planning, resource navigation, consultation, or referral.
Participants will also receive the FamilyStrong Navigation Companion, a caregiver-directed resource containing check-in pages, caregiving resources, medical and appointment organizers, worksheets, and notes pages.
Additional follow-up contacts may occur based on caregiver needs.
|
|
Sem intervenção: Usual care
Caregivers randomized to usual care will continue to use the supportive services ordinarily available through the UAB cancer center, health system, community organizations, and their personal support networks.
The study will not restrict access to social work, chaplaincy, behavioral health, palliative care, patient navigation, support groups, or other services.
Participants will receive a study-approved packet describing available cancer-center and family-support resources but will not receive the monthly FamilyStrong navigator contacts during the 24-week study period.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Acceptability of FamilyStrong Assessed by the Theoretical Framework of Acceptability Questionnaire
Prazo: 24 weeks after randomization
|
Intervention-group caregivers will complete the Theoretical Framework of Acceptability questionnaire, which assesses affective attitude, burden, ethicality, intervention coherence, opportunity costs, perceived effectiveness, and self-efficacy.
The outcome will be the mean questionnaire score.
A mean score of at least 4 is the prespecified benchmark indicating acceptable intervention delivery.
|
24 weeks after randomization
|
|
Feasibility: FamilyStrong Intervention Completion Rate
Prazo: 24 weeks
|
Percentage of eligible, scheduled FamilyStrong encounters completed by intervention-group caregivers.
A completed encounter includes administration of the Caregiver Distress Thermometer, Problem List, "Bothers Most," and "Would Like Assistance With" questions, with individualized support provided as indicated.
Encounters scheduled after withdrawal or patient death are excluded from the denominator.
The feasibility benchmark is at least 80% completion.
|
24 weeks
|
|
Feasibility: Study Assessment Completion Rate
Prazo: 24 weeks
|
Percentage of baseline and 24-week study assessments completed by eligible caregiver and optional patient participants.
Assessments not administered because of patient death or withdrawal will be reported separately and will not be counted as incomplete.
The prespecified feasibility benchmark is at least 80% completion.
|
24 weeks
|
|
Feasibility: Caregiver Retention Rate
Prazo: From randomization through the final applicable study activity, approximately 24 weeks
|
Percentage of randomized caregiver participants who remain enrolled through completion of their final protocol-applicable study activity.
Caregivers whose patient dies before week 24 will not be considered lost solely because the week-24 quantitative assessment is not administered.
|
From randomization through the final applicable study activity, approximately 24 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Caregivers: Hospital Anxiety and Depression Scale (anxiety symptoms)
Prazo: Baseline and 24 weeks
|
Caregiver anxiety symptoms will be measured using the seven-item anxiety subscale of the Hospital Anxiety and Depression Scale.
Subscale scores range from 0 to 21, with higher scores indicating greater anxiety symptoms.
The outcome is the change in score from baseline to 24 weeks after randomization.
|
Baseline and 24 weeks
|
|
Caregivers: Hospital Anxiety and Depression Scale (depressive symptoms)
Prazo: Baseline and 24 weeks
|
Caregiver depressive symptoms will be measured using the seven-item depression subscale of the Hospital Anxiety and Depression Scale.
Higher scores indicate greater depressive symptoms.
The outcome is the change in depression subscale score from baseline to 24 weeks after randomization.
|
Baseline and 24 weeks
|
|
Caregivers: PROMIS Global Health 10 (physical health quality of life)
Prazo: Baseline and 24 weeks
|
Caregiver physical health-related quality of life will be measured using the physical health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better physical health-related quality of life.
The outcome is the change in score from baseline to 24 weeks after randomization.
|
Baseline and 24 weeks
|
|
Caregivers: PROMIS Global Health 10 (mental health quality of life)
Prazo: Baseline and 24 weeks
|
Caregiver mental health-related quality of life will be measured using the mental health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better mental health-related quality of life.
|
Baseline and 24 weeks
|
|
Caregivers: Cancer Survivors' Partners Unmet Needs Measure (CaSPUN)
Prazo: Baseline and 24 weeks
|
Caregiver unmet supportive care needs will be measured using the 35-item Cancer Survivors' Partners Unmet Needs Measure (CaSPUN).
The measure assesses unmet needs across information, quality of life, emotional and relationship, and life-perspective domains.
Higher scores indicate greater unmet needs.
|
Baseline and 24 weeks
|
|
Patients: Hospital Anxiety and Depression Scale (anxiety symptoms)
Prazo: Baseline and 24 weeks
|
Anxiety symptoms among optional patient participants will be measured using the seven-item anxiety subscale of the Hospital Anxiety and Depression Scale.
Higher scores indicate greater anxiety symptoms.
|
Baseline and 24 weeks
|
|
Patients: Hospital Anxiety and Depression Scale (depressive symptoms)
Prazo: Baseline and 24 weeks
|
Depressive symptoms among optional patient participants will be measured using the seven-item depression subscale of the Hospital Anxiety and Depression Scale.
Higher scores indicate greater depressive symptoms.
|
Baseline and 24 weeks
|
|
Patients: PROMIS Global Health 10 (physical quality of life)
Prazo: Baseline and 24 weeks
|
Physical health-related quality of life among optional patient participants will be measured using the physical health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better physical health-related quality of life.
|
Baseline and 24 weeks
|
|
Patients: PROMIS Global Health 10 (mental health quality of life)
Prazo: Baseline and 24 weeks
|
Mental health-related quality of life among optional patient participants will be measured using the mental health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better mental health-related quality of life.
|
Baseline and 24 weeks
|
|
Patients: Cancer Survivors' Unmet Needs Measure (CaSUN)
Prazo: Baseline and 24 weeks
|
Unmet supportive care needs among optional patient participants will be measured using the 35-item adapted Cancer Survivors' Unmet Needs Measure (CaSUN).
The measure assesses needs related to information and medical care, quality of life, emotional and relationship concerns, and life perspective.
Higher scores indicate greater unmet needs.
|
Baseline and 24 weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de janeiro de 2027
Conclusão Primária (Estimado)
31 de março de 2028
Conclusão do estudo (Estimado)
30 de setembro de 2028
Datas de inscrição no estudo
Enviado pela primeira vez
6 de agosto de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
6 de agosto de 2026
Primeira postagem (Real)
13 de agosto de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
13 de agosto de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
6 de agosto de 2026
Última verificação
1 de agosto de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- IRB-300017196
- DBG-26-1598921-01-CTPS-W25 (Número de outro subsídio/financiamento: American Cancer Society)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
SIM
Descrição do plano IPD
De-identified individual participant data underlying the primary published results may be shared with qualified researchers following completion of the primary analyses and publication.
Shared data may include quantitative caregiver and patient questionnaire data and relevant intervention-process data, together with a data dictionary.
Audio recordings, direct identifiers, and data presenting an unreasonable risk of participant re-identification will not be shared.
Access will require an approved research proposal, execution of a data-use agreement, and applicable UAB, Institutional Review Board, sponsor, and participant-consent requirements.
Prazo de Compartilhamento de IPD
Data will become available beginning approximately 12 months after publication of the primary study findings and will remain available for at least 5 years.
Critérios de acesso de compartilhamento IPD
Requests will be reviewed by the Principal Investigator and appropriate UAB research officials.
Access may be provided to qualified researchers whose proposed analyses have a scientifically sound purpose and are consistent with participant consent and applicable regulatory, institutional, and sponsor requirements.
Approved requestors must execute a data-use agreement and agree to protect confidentiality, use the data only for the approved purpose, and not attempt to identify participants.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- ANALYTIC_CODE
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .